All In Biotech

Drug Trial Radar · NCT01722539

Impact IPT With Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine in Schoolchildren

Efficacy and Safety of Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine Regimens Delivered Through Intermittent Preventive Treatment in Schoolchildren of Democratic Republic of Congo: A Randomised Control Trial

Last checked: Nov 20, 2026Latest source record: Feb 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 616 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

616

Actual

Start

Nov 2012

Primary completion

Nov 2013

Study completion Nov 2013

Sponsor

Lead sponsor
Universiteit AntwerpenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Fund for Scientific Research, Flanders, Belgium; University of Kinshasa
First posted
Nov 7, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 5 years, up to 14 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Considering the facts that: (i) IPT of malaria provides substantial protection against anaemia and malaria in school children (ii); SP resistance has no significant impact on the prophylactic efficacy (iii) SP-PQ is safe and as efficacious as SP: the investigators hypothesize that antimalarial IPT with SP and SP-PQ will improve haemoglobin concentration, reduce anaemia prevalence, malaria incidence and parasitaemia, and improve malnutrition and school performance in school-aged children of Congo.

Conditions

  • Healthy

Interventions

  • Sulfadoxine-pyrimethamineDrug

    Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more

  • PiperaquineDrug

    Piperaquine tablet 320 mg manufactured by Sigma Tau will be used at two treatment doses of 16-24 mg/kg at 24 hours intervals as follows: 1 tablets for weigh 15-19 kg, 1.5 tablets for 20-29 kg, and 2 tablets for 30-39 kg, and 2.5 tablets for 40 kg or more.

  • AlbendazoleDrug

    One oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.

  • PraziquantelDrug

    Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hemoglobin changeTime frame: Month 0-Month 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mokali health area of Biyela health zone, in Kinshasa province.

    Kinshasa, Kinshasa Province, Republic of the Congo

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.